In today’s session Nektar Therapeutics (NKTR) recorded an unusually high (307) contracts volume of put trades. Someone, most probably a professional was a very active buyer of the May, 2017 put, expecting serious NKTR decrease. With 307 contracts traded and 22294 open interest for the May, 17 contract, it seems this is a quite bearish bet. The option with symbol: NKTR170519P00010000 closed last at: $1 or 0% . About 145,817 shares traded hands. Nektar Therapeutics (NASDAQ:NKTR) has declined 11.30% since April 18, 2016 and is downtrending. It has underperformed by 15.73% the S&P500.
Nektar Therapeutics (NASDAQ:NKTR) Ratings Coverage
Out of 3 analysts covering Nektar Therapeutics (NASDAQ:NKTR), 3 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Nektar Therapeutics has been the topic of 5 analyst reports since August 6, 2015 according to StockzIntelligence Inc. As per Monday, September 21, the company rating was maintained by Roth Capital. Aegis Capital initiated Nektar Therapeutics (NASDAQ:NKTR) on Tuesday, November 8 with “Buy” rating. TheStreet downgraded the stock to “Hold” rating in Wednesday, August 26 report. Piper Jaffray maintained Nektar Therapeutics (NASDAQ:NKTR) rating on Thursday, January 7. Piper Jaffray has “Overweight” rating and $20.0 price target.
According to Zacks Investment Research, “Nektar Therapeutics is a clinical-stage biopharmaceutical company developing a pipeline of drug candidates that utilize its PEGylation and polymer conjugate technology platforms, which are designed to meet unmet medical needs and improve the benefits of drugs for patients. Its product pipeline consists of drug candidates across a number of therapeutic areas, including oncology, pain. In the area of pain, Nektar has a worldwide license agreement with AstraZeneca for NKTR-118, an investigational drug candidate, being evaluated in Phase 3 clinical studies as a once-daily, oral tablet for the treatment of opioid-induced constipation. The agreement also includes NKTR-119, an earlier stage development program that is a co-formulation of NKTR-118 and an opioid. Also in the area of pain, NKTR-181, the company’s wholly-owned novel mu-opioid analgesic molecule, is being evaluated in Phase 1 clinical studies. Nektar Therapeutics is headquartered in San Francisco, California.”
Insitutional Activity: The institutional sentiment increased to 1.29 in 2016 Q2. Its up 0.15, from 1.14 in 2016Q1. The ratio improved, as 16 funds sold all Nektar Therapeutics shares owned while 56 reduced positions. 22 funds bought stakes while 60 increased positions. They now own 131.60 million shares or 3.23% less from 135.99 million shares in 2016Q1.
Shell Asset Mgmt accumulated 0.02% or 46,763 shares. Moreover, Cormorant Asset Ltd Com has 4.08% invested in Nektar Therapeutics (NASDAQ:NKTR) for 2.02 million shares. Allianz Asset Mngmt Ag holds 0% of its portfolio in Nektar Therapeutics (NASDAQ:NKTR) for 208,902 shares. Barclays Public Limited Company holds 11,324 shares or 0% of its portfolio. Aperio Group Limited Com has 0% invested in the company for 27,004 shares. Morgan Stanley accumulated 0% or 479,963 shares. Legal General Gru Public Limited Co has 0% invested in the company for 33,763 shares. Ameriprise accumulated 0.01% or 658,966 shares. Opus Point Mgmt Limited holds 178,531 shares or 2.45% of its portfolio. Profund Advisors Ltd holds 0.01% of its portfolio in Nektar Therapeutics (NASDAQ:NKTR) for 17,625 shares. Moreover, Fred Alger Mngmt has 0% invested in Nektar Therapeutics (NASDAQ:NKTR) for 40,000 shares. Plante Moran Finance Ltd, a Michigan-based fund reported 72 shares. Proshare Ltd Company has 120,322 shares for 0.02% of their US portfolio. Great West Life Assurance Communication Can owns 14,594 shares or 0% of their US portfolio. Primecap Mngmt Com Ca reported 20.00 million shares or 0.3% of all its holdings.
Insider Transactions: Since June 1, 2016, the stock had 1 buying transaction, and 16 insider sales for $5.64 million net activity. CHESS ROBERT also sold $230,520 worth of Nektar Therapeutics (NASDAQ:NKTR) on Thursday, September 15. GREER R SCOTT had bought 15,000 shares worth $202,500 on Monday, October 24. Gergel Ivan P. also sold $29,589 worth of Nektar Therapeutics (NASDAQ:NKTR) on Tuesday, August 16. The insider Hora Maninder sold $58,036. Doberstein Stephen K sold $23,460 worth of stock. 3,317 shares were sold by Nicholson John, worth $58,247. On Thursday, September 1 ROBIN HOWARD W sold $1.56M worth of the stock or 87,500 shares.
Nektar Therapeutics is a biopharmaceutical company. The company has a market cap of $2.04 billion. The Firm is engaged in the development of a pipeline of drug candidates that utilize its PEGylation and advanced polymer conjugate technology platforms, which are designed to enable the development of new molecular entities that target known mechanisms of action. It currently has negative earnings. The Company’s pipeline consists of drug candidates for therapeutic areas, including oncology, pain, anti-infectives and immunology.
NKTR Company Profile
Nektar Therapeutics, incorporated on June 3, 1998, is a clinical-stage biopharmaceutical company. The Firm is developing a pipeline of drug candidates that utilizes its PEGylation and advanced polymer conjugate technology platforms, which are designed to enable the development of molecular entities that targets known mechanisms of action. The Company’s pipeline is comprised of drug candidates across a number of therapeutic areas including oncology, pain, anti-infectives and immunology. The Companyâ€™s research and development activities involve small molecule drugs, peptides and other biologic drug candidates.
More notable recent Nektar Therapeutics (NASDAQ:NKTR) news were published by: Cnbc.com which released: “Nektar Therapeutics shares fall on secondary stock offering” on October 19, 2016, also Prnewswire.com with their article: “Nektar Therapeutics to Present at Jefferies 2016 Global Healthcare Conference …” published on November 14, 2016, Prnewswire.com published: “Nektar Therapeutics Presents New Clinical Data from Ongoing Phase 1 Dose …” on November 09, 2016. More interesting news about Nektar Therapeutics (NASDAQ:NKTR) were released by: Prnewswire.com and their article: “Nektar Therapeutics Announces Upcoming Presentations at the 2016 Society for …” published on October 28, 2016 as well as Seekingalpha.com‘s news article titled: “Nektar Therapeutics’ (NKTR) CEO Howard Robin on Q3 2016 Results – Earnings …” with publication date: November 04, 2016.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.